NIH issued one RFA last week, for cellular therapies to treat radiation injuries. In that one RFA, the National Institute of Allergy and Infectious Diseases committed $4 million for FY 2018. The maximum project length is five years, although future appropriations will determine funding levels past FY 2018.
Why am I pointing this out? Because this is twice the level of commitment that NIAID is making to the ME/CFS RFAs. Understand this. The science of cellular treatments for radiation exposures is more advanced than the science of ME/CFS, such that $4 million is being allocated for this narrow RFA. And NIAID is investing half as much in the ME/CFS RFAs which are intended to build a major infrastructure piece of our entire field.
We have a very very long way to go, friends.
Here are the current cumulative RFA numbers:
|FY 2017||FY 2016|
|RFAs for ME/CFS||TWO||ZERO|
And here is the table for FY 2017 alone:
|Week Beginning||RFAs Issued||Total Commitment||RFAs for ME/CFS|
If you want more background on the RFA Ticker, read the inaugural post.